← All trials
NCT04673864
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 17, 2021
- Primary completion
- Mar 4, 2021
- Completion date
- Mar 30, 2021
- First posted
- Dec 17, 2020
- Last posted
- Jul 7, 2021
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- H Plus Yangji HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.